BDNF and attention deficit-hyperactivity disorder: Pharmacological targeting of BDNF itself is difficult, but treatment with a D3R agonist pre-pubertally may reduce behaviors that are associated with ADHD, including risk for SUD, changes in object recognition, and activity levels.